Getting to Know Cells
Cells make up every living thing. Inside of each cell are genetic instructions which determine what cell type it will be, and how the cell will behave. All individuals begin with a pool of cells that are the foundation cells for every organ and tissue in the body. These cells are called stem cells which are immature cells that will divide into many different types of mature, specialized cells depending on what the body needs this is called differentiation. During this process, a set of genes in the DNA of each cell are turned on or off to determine what type of cell it will turn into and what type of proteins it will create to help the body function. For example, a stem cell may be instructed, directly or indirectly, by the genes to travel to an area of the body for muscle contraction. These will become muscle cells and continue to divide and play a role in contracting ones muscles for movement. Once a stem cell becomes a mature cell, it will stay that cell type. Throughout one's life, stem cells turn into mature cells, but certain parts of the body will keep their own supply of stem cells, such as in our bone marrow.
The processes of cell growth, division, and differentiation can be complex. When cells grow old or become damaged, they usually die, and new cells get created to divide and to take their place. However, there are times when the body is not able to recognize a cell change, and a damaged cell continues to replicate with changed DNA. A change in the DNA changes how our cells function because it affects how the proteins in our body are built. These changes can be inherited, can happen as we age, or can be caused by environmental factors.
Many human diseases are caused by our cells not functioning properly. For example, in some types of cancer, specific cells in the body get stuck somewhere along the long path of differentiation, creating a shortage of the cell type they had intended to make. The body then tries to compensate for this shortage by having these potentially damaged cells divide many times to fill the gap. This adds to the problem by filling up the tissue with non-functional cells that will take over the normal healthy cells to survive.
Cell therapy is the transfer of a specific cell type, or types, into a person to treat or prevent a disease. Many cell types have the potential to be modified and used as a therapy. Common disorders treated with cellular therapies include cancers of the blood and bone marrow, cancers of the lymphatic system, plasma cell disorders, and other conditions that affect the bodys ability to make healthy cells.
The source of the cells used for cell therapy come from one of two places:
Autologous cell therapy means the cells are collected from the individual's own body. The cells are removed, modified outside the body, then the processed cells are returned to the body. Using the person's own cells makes it less likely to cause immune responses compared to the use of donor cells but will not always be a viable option. A helpful tip to remember is that auto means self.
Allogeneic cell therapy means the cells used are from someone other than the patient, such as a healthy and compatible (or matched) donor. A helpful tip to remember this is that allo means other.
Prior to receiving a cell therapy, an individual may need to follow a pretreatment called conditioning to decrease the immune system's activity for better odds of a successful treatment. Conditioning is often a chemotherapy, which can be extremely hard on the body. It is important that all aspects of the treatment process be thoroughly explained by a healthcare professional to ensure it is well understood by the patient.
Gene modified cell therapy (or ex vivo gene therapy) is a combination of both gene and cell therapy. It first removes a persons own cells from the body. Certain cell types are then treated by either adding a working copy of the gene or modifying/editing the affected nonfunctional gene. Ideally, the body will continue to produce mature cells with the modification when administered back to the individual. CART-cell therapy is just one example of this, but other approved treatments include cells that are modified with lentivirus for disorders such as server combined immunodeficiency (SCID), and metachromatic leukodystrophy (MLD).
Learn more about gene therapy basics and various gene and cell therapy approaches.
The type of cells used for cell therapy depends on the disease being treated and the intended effect on the individual receiving treatment. Here are few commonly used types:
Hematopoietic (blood forming) stem cells also known as HSCs are versatile cells that can turn into any type of blood cell the body needs and can be retrieved from the peripheral blood, from the bone marrow or from umbilical cord blood. Treatments using these cells aim to establish healthy blood cell production in individuals whose blood cells or immune cells are not working properly. A hematopoietic stem cell transplantation (HSCT), sometimes known as a bone marrow transplant (BMT), is used to treat various blood cancers and other blood disorders. HSCs are usually from a donor (allogeneic), but in some cases may use cells collected from the persons own body (autologous).
Cells of the immune system are used because they can recognize and kill cancer cells. One type of cell therapy, called CAR T-cell therapy, modifies the individual's immune cells called T-cells by adding receptors to them. When these modified cells are delivered back to the patient, they recognize, and kill cancer cells. CAR-T typically uses a persons own cells (autologous) but in some cases, may utilize cells collected from a donor (allogenic).
Learn more about blood disorders and this treatment process in CAR T Basics.
Mesenchymal stem cells, most commonly found in bone marrow and fat, are the most versatile and can help the body heal in different ways depending on what is being targeted. They can act like stem cells and become the same type of cell as those in the surrounding area or act like a delivery system to bring medicine to the area in need.
Hope for life-limiting disease.Cell and gene therapy can help treat diseases that have limited treatment options. Without treatment many of these inherited disorders would end in severe disability or premature death. In early studies cell and gene therapy have been shown to help slow or completely stop these disorders. Cell and gene therapies make it possible to design treatments that can target any of the thousands of genes in the body.
Matched donors. Similar to human organ transplants, immune barriers exist that require the person donating the HSC and person receiving the HSC to be carefully matched to avoid life-threatening complications arising from immune system not matching. Many individuals may never find someone who is a match due to lack of recruitment, diversity, and availability.
Accuracy required.Cell and genetherapies need to ensure modified cells go to the right tissue, at the right level, for the right amount of time. This means that a lot of research goes intothe best waytodeliver the cellular material.
Immune suppression. Chemotherapy and other conditioning regimens are often administered prior to cell therapy to prevent an immune response. The medications used to suppress an individuals immune system can increase their risk for infections and can be quite hard on the body.
Informed consent. Before participating in a clinical trial or receiving a cell therapy treatment, a member of the research team should review any potential risks and benefits with the individual and/or caregiver. It is important that individuals participating in a clinical trial understand their rights during the research process and know what to expect.
Immune responses. Graft-versus-host disease (GVHD), a syndrome that arises when immune cells present in the, transplanted HSC (the graft) recognize the recipient/hosts cells/tissues as foreign and mount an immune response that leads to the destruction of multiple host tissues.
Organ toxicities. During CAR-T therapy, immune system cells become stimulated and release chemical messengers called cytokines. Too many cytokines can result in fever, trouble breathing and can be life-threatening. In the case of cytokine release syndrome, individuals may require anti-cytokine therapy.
Next, visit CAR T Basics to learn more about approved cell therapies, and cell therapy use in disease treatments for blood disorders.
Was this information helpful?If so, please share! All ASGCT Patient Education resources are free touse bysharingon social media,embeddingthevideo, orsimply linking tothis page!Please credit the American Society of Gene and Cell Therapyor tag@ASGCTherapy.
Read the rest here:
Cell Therapy Basics
- FDA Approves Amtagvi, First Cell Therapy for Skin Cancer - BioPharm International - February 21st, 2024
- Cellenkos Approved to Proceed with CK0803 Neurotrophic T regulatory Cell therapy to Treat Second Cohort in ALS Trial - PR Newswire - February 21st, 2024
- Astellas and Kelonia enter CAR-T cell therapy collaboration worth over $800m - PMLiVE - February 21st, 2024
- Bridging Therapy With CAR T-Cell Therapy in LBCL - OncLive - February 21st, 2024
- FDA approves first cell therapy to treat aggressive forms of melanoma - NPR - February 21st, 2024
- Iovance, with approval of 'TIL' cell therapy, readies for complex launch - Yahoo Finance - February 21st, 2024
- Cancer treatment: FDA approves type of cell therapy for patients with late-stage melanoma - FOX 26 Houston - February 21st, 2024
- Pharmalittle: We're reading about weight loss drugs, a cell therapy for melanoma, and more - STAT - February 21st, 2024
- On heels of cancer cell therapy win, Peninsula biotech looks to raise $211M - San Francisco Business Times - The Business Journals - February 21st, 2024
- FDA approves cell therapy to treat melanoma - FOX 26 Houston - February 21st, 2024
- Toddler Beats Childhood Leukemia After Car T-Cell Therapy - City of Hope - February 21st, 2024
- FDA Approves First One-time Cell Therapy for a Solid Tumor - BioSpace - February 21st, 2024
- Iovance wins FDA approval for cell therapy - BioProcess Insider - BioProcess Insider - February 21st, 2024
- FDA Approves Iovance Cancer Treatment, the First Cell Therapy for a Solid Tumor - MedCity News - February 21st, 2024
- Promising target for CAR T-cell therapy leads to potent antitumor responses against cutaneous and rare melanomas - Medical Xpress - February 21st, 2024
- Reinforcing Cell Therapy with Microfluidic Cell Sorting - RegMedNet - February 21st, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 21st, 2024
- Understanding CAR T-Cell Therapy: Balancing the Risks and Benefits - Medriva - February 21st, 2024
- Keeping Track: Iovance's Amtaqvi Approval Brings T Cell Therapy To Solid Tumors - Pink Sheet - February 21st, 2024
- Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be ... - Yahoo Finance - February 21st, 2024
- What is CAR-T cell therapy, used for cancer treatment? Experts explain - India Today - India Today - February 21st, 2024
- UPDATE: 2seventy splits once more, sending cell therapy pipeline to Regeneron in 'dramatic' change - FierceBiotech - January 31st, 2024
- Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction - News-Medical.Net - January 31st, 2024
- BioCardia Pivots to Biomarker Strategy to Prove Heart Failure Cell Therapy Benefits - precisionmedicineonline.com - January 31st, 2024
- Sequencing With CAR T-Cell Therapy for LBCL - OncLive - January 31st, 2024
- Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy ... - pnas.org - January 31st, 2024
- Regeneron to acquire 2seventy's cell therapy pipeline - Yahoo Finance - January 31st, 2024
- Trial of cell-based therapy CK08031 finishes dosing 1st patients - ALS News Today - January 31st, 2024
- Exploring Gene and Cell Therapy Integration in Pharmacies - PharmaNewsIntel - January 31st, 2024
- HBS Alumna Fighting Cancer with a Novel Cell Therapy - MBA - hbs.edu - January 31st, 2024
- YUHS partners with KURE.AI Therapeutics for cell therapy development - KBR - January 31st, 2024
- Global CAR-T Cell Therapy Market Report 2024-2034: Accelerated Growth Fueled by Intensive R&D, Growing Medical ... - Yahoo Finance - January 31st, 2024
- Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy ... - PR Newswire - January 31st, 2024
- A new chapter in cell therapy: engineered B cells reach the clinic for the first time - Labiotech.eu - January 31st, 2024
- Harnessing the Dark Genome: New Approach Greatly Improves Cancer T-Cell Therapy - SciTechDaily - January 31st, 2024
- Cell therapies | Harvard Stem Cell Institute (HSCI) - November 16th, 2023
- Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological... - April 15th, 2023
- Basal Cell Carcinoma Treatment - The Skin Cancer Foundation - January 4th, 2023
- Adoptive Cell Therapy - Cancer Research Institute (CRI) - December 27th, 2022
- National Medical Commission prohibits use of stem cell therapy to treat patients with autism - Hindustan Times - December 18th, 2022
- Tumor buster - where will the CAR-T cell therapy missile go? - December 18th, 2022
- Gilead lands new cell therapy for Kite in $225M Arcellx deal, providing global scale for future J&J-Legend showdown - FierceBiotech - December 10th, 2022
- Non-Small Cell Lung Cancer Treatment (PDQ)Patient Version - November 24th, 2022
- CAR-T Cell Therapy Program - Frequently asked questions - November 24th, 2022
- EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell... - November 24th, 2022
- Radiation Therapy for Non-Small Cell Lung Cancer - November 6th, 2022
- AvenCell to Present New Data from Lead Universal CAR T Cell Therapy Program at 64th American Society of Hematology Annual Meeting and Exposition -... - November 6th, 2022
- Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials - MarketWatch - November 6th, 2022
- Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem, a Novel Cell Therapy for the... - November 6th, 2022
- Photodynamic Therapy to Treat Cancer - NCI - October 29th, 2022
- Researchers at University Hospitals create a breakthrough in CAR-T cell therapy for cancer patients - News 5 Cleveland WEWS - October 29th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 29th, 2022
- Gilead, working to improve cancer cell therapy, partners with California startup - BioPharma Dive - October 21st, 2022
- Allogene starts first pivotal trials of an 'off-the-shelf' cell therapy for cancer - BioPharma Dive - October 13th, 2022
- Vita Therapeutics Closes $31 Million Series B Financing to Develop Cell Therapies for Neuromuscular Diseases and Cancers - Business Wire - October 13th, 2022
- CAR T-cell Therapy Market Riding on the Wave of Growth and will Grow at a CAGR of 30.6% to 2031 | TMR Study - GlobeNewswire - October 13th, 2022
- Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors - PR Newswire - October 13th, 2022
- Cell Therapy Technologies Market Expected to Reach US ~$12.27 Billion and CAGR 14.5% by 2030 Polaris Market Research - Digital Journal - October 13th, 2022
- Early Data on GPRC5D-Directed CAR T-Cell Therapy Open Doors for New Myeloma Treatment Strategies - Precision Oncology News - October 13th, 2022
- BREAKTHROUGH TECHNOLOGY FOR IPS-DERIVED CELL THERAPIES TURNED INTO GMP PLATFORM BY TREEFROG THERAPEUTICS & INVETECH - PR Newswire - October 13th, 2022
- Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases -... - October 13th, 2022
- Breast cancer treatment: These targeted therapies are a ray of hope for patients - Health shots - October 13th, 2022
- Two-Year Clinical Data for DiscGenics's Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented at NASS 2022 - PR Newswire - October 13th, 2022
- Mayo Clinic Minute: What is CAR-T cell therapy? - Finger Lakes Times - October 13th, 2022
- Gamma Biosciences and Lonza Collaborate to Co-develop Reagents for Clinical Cell Selection in the Cocoon Platform USA - English - USA - English - PR... - October 13th, 2022
- Merck and Moderna Move Forward with Personalized Cancer Vaccine - BioSpace - October 13th, 2022
- First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study - Targeted Oncology - October 13th, 2022
- MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022 - Yahoo Finance - October 13th, 2022
- Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy - GlobeNewswire - October 13th, 2022
- Elicera Therapeutics: PhD thesis describing the iTANK-platform awarded best of the year 2021 in Sweden in the field of gene and cell therapy -... - October 13th, 2022
- Integrating CAR T-Cell Therapy Into Community Oncology Practices - Targeted Oncology - October 4th, 2022
- About CAR-T cell therapy - Mayo Clinic - October 4th, 2022
- Autologous immune-cell therapy, practiced in Japan, now helping Vinmec Hospital, treat cancer patients in Hanoi, Vietnam, after technology transfer by... - October 4th, 2022
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B... - October 4th, 2022
- Regenerative Spine and Pain Institute: Treating Pain with PRP and Stem Cell Therapy - Community News - October 4th, 2022
- City of Hope To Accelerate Immunotherapy Research And Treatment Innovation with $15 Million Gift From Ted Schwartz Family - City of Hope - October 4th, 2022
- Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel - Business Wire - October 4th, 2022
- Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors - Yahoo Finance - October 4th, 2022
- SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy -... - October 4th, 2022
- ArchiMed invests in PlasmidFactory, a German gene and cell therapy specialist - BSA bureau - October 4th, 2022